Bristol CAR-T trial death in autoimmune study; Roche lung cancer drug news

Bristol Myers Squibb disclosed a patient death in an early-stage trial of its investigational CAR-T therapy for autoimmune disease, raising safety concerns for the program. The cause and details remain undisclosed, and the impact on the development timeline is uncertain. This is a notable safety signal in a high-profile cell therapy area.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works